Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination immune response study in metastatic RCC or GIST patients treated with sunitinib or sorafenib
NL-OMON32710Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2008
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of sunitinib, sorafenib and influenza vaccine in renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) (3 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Cellular immune response to influenza vaccination and Humoral immune response to influenza vaccination. Planned start Oct 2008; status: not yet recruiting.
02
Drugs
sunitinibsorafenibinfluenza vaccine
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON32710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32710.